"Taxoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Descriptor ID |
D043823
|
MeSH Number(s) |
D02.455.426.392.368.242.888 D02.455.849.291.850
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Taxoids".
Below are MeSH descriptors whose meaning is more specific than "Taxoids".
This graph shows the total number of publications written about "Taxoids" by people in this website by year, and whether "Taxoids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 5 | 0 | 5 |
1996 | 1 | 0 | 1 |
1997 | 6 | 0 | 6 |
1998 | 9 | 1 | 10 |
1999 | 7 | 1 | 8 |
2000 | 13 | 0 | 13 |
2001 | 9 | 0 | 9 |
2002 | 17 | 1 | 18 |
2003 | 16 | 2 | 18 |
2004 | 12 | 5 | 17 |
2005 | 9 | 16 | 25 |
2006 | 8 | 20 | 28 |
2007 | 10 | 15 | 25 |
2008 | 13 | 15 | 28 |
2009 | 7 | 9 | 16 |
2010 | 4 | 22 | 26 |
2011 | 12 | 19 | 31 |
2012 | 5 | 16 | 21 |
2013 | 6 | 18 | 24 |
2014 | 3 | 12 | 15 |
2015 | 8 | 12 | 20 |
2016 | 3 | 14 | 17 |
2017 | 7 | 12 | 19 |
2018 | 3 | 4 | 7 |
2019 | 1 | 3 | 4 |
2020 | 1 | 4 | 5 |
2021 | 1 | 4 | 5 |
2022 | 0 | 2 | 2 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Taxoids" by people in Profiles.
-
Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist. 2023 Dec 11; 28(12):e1303-e1305.
-
Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer. Prostate. 2023 07; 83(10):950-961.
-
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 10; 10(10).
-
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis. Breast Cancer Res Treat. 2022 Aug; 194(3):597-606.
-
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021 12 15; 13(624):eabj5070.
-
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
-
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
-
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.
-
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Jan 01; 7(1):61-69.
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.